Nuclear Receptor Disease State Targets

Supercharge your drug discovery and development with INDIGO Biosciences' cell-based assays. Gain deep insights by unlocking the potential of multi-target interactions for enhanced therapeutic efficacy. Transform your research today!

Disease-States-740x487-1
disease-state-pill-pic4

Unlock the power of polypharmacology with INDIGO Biosciences' advanced solutions and revolutionize your drug discovery efforts.

  • Target specific disease mechanisms with precision and effectiveness
  • Get holistic evaluation for enhanced compound efficacy and safety
  • Maximize therapeutic potential by targeting multiple pathways simultaneously

Harness Polypharmacology to Improve the Potential for Clinical Efficacy

Advances in systems biology are revealing a phenotypic robustness and a network structure that strongly suggests that exquisitely selective compounds, compared with multi-target drugs, may exhibit lower than desired clinical efficacy. This new appreciation of the role of polypharmacology has significant implications for the two major sources of attrition in drug development, efficacy, and toxicity. Thus defining the biological niche of each receptor as well as understanding overlapping pathways and functions provides valuable context for evaluating a compound’s liabilities and promise.

Defining the system that each receptor participates in can be approached in several ways, such as sequence similarity, potential disease implication, or transcriptional networks. By choosing a select group of receptors to study based on disease state, it is possible to better understand the biological effects of your compounds. With INDIGO's extensive portfolio of receptor assays, you can design your own panel based on a disease state or talk to our experts to assist in developing a plan of study.

Applications for INDIGO’s Luciferase Reporter Assays

reporter_assay_drug_discovery

Rapidly evaluate the efficacy and safety profile of a drug candidate with INDIGO’s Reporter Assay Services and streamline the development process to safer, more effective pharmaceutical agents.

enviornment_block_img

Effectively screen environmental samples, with INDIGO’s Reporter Assay Services and actively contribute to building a safer environment.

diesease_state_block

Quickly gain insights into the mechanisms underlying the involvement of key receptors in various diseases with INDIGO’s Reporter Assay Services.

Related Information

Nuclear Receptors and Their Classifications

Cell@2x

How Nuclear Receptor Profiling Can Determine the Fate of Your Compounds

Nuclear-Receptor@2x

How to Develop Testing Strategy for EDCs in Water Resources

Waters@2x

Profiling Drug Activity of Human and Ortholog Xenobiotic-Sensing Receptors: PXR, CAR, AhR, and FXR - INDIGO Biosciences

Profiling-Drug-Activity-of-Human-and-Ortholog-Xenobiotic-Sensing-Receptors_-PXR,-CAR,-AhR,-and-FXR---INDIGO-Biosciences

Regulation of Steatosis in upcyte® Hepatocytes by Nuclear Receptor Agnostics

Regulation-of-Steatosis-in-upcyte®-Hepatocytes-by-Nuclear-Receptor-Agnostics

Correlation Between Cytochrome P450 Inducers and Nuclear Receptor Activation - a Screening Approach - INDIGO Biosciences

Correlation-Between-Cytochrome-P450-Inducers-and-Nuclear-Receptor-Activation---a-Screening-Approach

Human CYP2B6 Produces Oxylipins from Polyunsaturated Fatty Acids and Reduces Diet-Induced Obesity

Disruption of the Tumor Suppressor-Like Activity of Aryl Hydrocarbon Receptor by Arsenic in Epithelial Cells and Human Lung Cancer

Effects-Based Monitoring of Bioactive Compounds Associated with Municipal Wastewater Treatment Plant Effluent Discharge to the South Platte River, Colorado, USA

What Our Customers Say

"I think if we had gone with anyone else, we would still be running assays rather than having confidence in the data that we've gained with INDIGO."

Mark

Principal Scientist

"The fact that they do have this comprehensive panel…essentially you can pick and choose which of the members of the panel you want to run."

Linda

Scientist

"The overall experience went smoothly, and I got valuable data that helped me advance several molecules through the discovery pipeline."

Olivia

Associate Director

Interested to know more about nuclear receptor assays?

Questions/Request a Quote